PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alembic Pharmaceuticals Limited (APLLTD.NS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISININE901L01018
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap₹188.19B
EPS₹30.06
PE Ratio31.85
Revenue (TTM)₹61.18B
Gross Profit (TTM)₹39.44B
EBITDA (TTM)₹8.62B
Year Range₹457.25 - ₹1,094.00
Target Price₹858.81

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with APLLTD.NS

Alembic Pharmaceuticals Limited

Performance

Performance Chart

The chart shows the growth of an initial investment of ₹10,000 in Alembic Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


500.00%1,000.00%1,500.00%2,000.00%2,500.00%OctoberNovemberDecember2024FebruaryMarch
2,366.66%
657.03%
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alembic Pharmaceuticals Limited had a return of 29.67% year-to-date (YTD) and 108.05% in the last 12 months. Over the past 10 years, Alembic Pharmaceuticals Limited had an annualized return of 14.82%, outperforming the S&P 500 benchmark which had an annualized return of 10.96%.


PeriodReturnBenchmark
Year-To-Date29.67%10.04%
1 month-5.99%3.53%
6 months29.71%22.79%
1 year108.05%32.16%
5 years (annualized)15.21%13.15%
10 years (annualized)14.82%10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202426.48%6.16%
20230.30%1.00%-9.10%4.59%1.82%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Alembic Pharmaceuticals Limited (APLLTD.NS) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
APLLTD.NS
Alembic Pharmaceuticals Limited
3.23
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Alembic Pharmaceuticals Limited Sharpe ratio is 3.23. A Sharpe ratio of 3.0 or higher is considered excellent.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00OctoberNovemberDecember2024FebruaryMarch
3.23
2.98
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

Dividends

Dividend History

Alembic Pharmaceuticals Limited granted a 0.81% dividend yield in the last twelve months. The annual payout for that period amounted to ₹8.00 per share.


PeriodTTM20232022202120202019201820172016201520142013
Dividend₹8.00₹8.00₹10.00₹14.00₹3.00₹5.50₹4.00₹4.00₹4.00₹3.50₹3.00₹2.50

Dividend yield

0.81%1.05%1.75%1.75%0.29%0.96%0.67%0.75%0.67%0.50%0.67%1.18%

Monthly Dividends

The table displays the monthly dividend distributions for Alembic Pharmaceuticals Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2024₹0.00₹0.00
2023₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹8.00₹0.00₹0.00₹0.00₹0.00₹0.00
2022₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹10.00₹0.00₹0.00₹0.00₹0.00
2021₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹14.00₹0.00₹0.00₹0.00₹0.00₹0.00
2020₹0.00₹0.00₹3.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00
2019₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹5.50₹0.00₹0.00₹0.00₹0.00₹0.00
2018₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00
2017₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00
2016₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00
2015₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.50₹0.00₹0.00₹0.00₹0.00₹0.00
2014₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00₹0.00₹0.00₹0.00₹0.00₹0.00
2013₹2.50₹0.00₹0.00₹0.00₹0.00₹0.00

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%0.8%
Alembic Pharmaceuticals Limited has a dividend yield of 0.81%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
200.0%400.0%600.0%800.0%26.6%
Alembic Pharmaceuticals Limited has a payout ratio of 26.64%, which is quite average when compared to the overall market. This suggests that Alembic Pharmaceuticals Limited strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-35.00%-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-8.95%
-0.05%
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alembic Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alembic Pharmaceuticals Limited was 57.14%, occurring on Mar 29, 2023. The portfolio has not yet recovered.

The current Alembic Pharmaceuticals Limited drawdown is 8.95%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-57.14%Dec 18, 2020566Mar 29, 2023
-45.05%Jul 17, 2015712Jun 5, 2018460Apr 24, 20201172
-27.58%Nov 9, 201137Jan 2, 201264Apr 2, 2012101
-23.65%Apr 28, 201415May 19, 201434Jul 4, 201449
-20.67%Jul 30, 201315Aug 21, 201334Oct 10, 201349

Volatility

Volatility Chart

The current Alembic Pharmaceuticals Limited volatility is 11.59%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%OctoberNovemberDecember2024FebruaryMarch
11.59%
2.90%
APLLTD.NS (Alembic Pharmaceuticals Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alembic Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items